1. Home

Protocols under development

On this page
Expand all Collapse all Back to top
ID Protocol
4119 BARD1 – risk management
4118 BRIP1 – risk management
4117 RAD51C and RAD51D – risk management
ID Protocol
   
ID Protocol
ID 4359 Allogeneic conditioning aplastic anaemia CYCLOPHOSPHamide fludarabine thymoglobuline and total body irradiation (TBI)
ID 4479 Allogeneic conditioning aplastic anaemia CYCLOPHOSPHamide ATGAM and total body irradiation (TBI)
ID 4480 Allogeneic conditioning fludarabine melphalan and total body irradiation (TBI)
ID 4481 Allogeneic conditioning busulfan fludarabine and thiotepa
ID 4428 Post-transplant cyclophosphamide
ID 4367 RVd 28 day protocol with once weekly bortezomib
ID 4284 Decitabine/cedazuridine – MDS/ AML/ CML
ID 4296 Aggressive non-Hodgkin lymphoma R-hyper CVAD (multi indication protocol)
ID 4429 Multiple myeloma teclistamab
ID 4453 Hodgkin lymphoma BEACOPDac
ID 4461 RR DLBCL Tafasitamab + Lenalidomide
ID 4454 RR DLBCL Glofitamab monotherapy with obinutuzumab pretreatment
ID 4472

B-cell acute lymphoblastic leukaemia brexucabtagene autoleucel
ID Protocol
4398

Head and neck oropharynx squamous cell carcinoma p16 positive adjuvant EBRT
4399

Head and neck palliative EBRT
4400

Non-Hodgkin extranodal indolent lymphoma EBRT
4401

Non-Hodgkin primary cutaneous T-cell lymphoma EBRT
4468

Prostate adenocarcinoma EBRT prostate bed and pelvic lymph nodes
4417

Pelvic lymph node metastases palliative stereotactic EBRT 
ID Protocol
4455 Breast adjuvant ribociclib
ID Protocol
4394 Colorectal metastatic trifluridine/tipiracil and bevacizumab
ID Protocol
4264 Endometrial advanced or recurrent dostarlimab (awaiting PBS)
ID Protocol
TBC Locally advanced or metastatic cabozantinib (thyroid cancer indications and evidence)
ID Protocol
4476 Glioma low grade recurrent vorasidenib
ID Protocol
4439 NSCLC locally advanced, recurrent or metastatic carboplatin pemetrexed and bevacizumab 
ID Protocol
ID TBA Rhabdomyosarcoma VAC (vincristine, dactinomycin, cyclophosphamide)
ID TBA Rhabdomyosarcoma IVA (ifosfamide, vincristine, dactinomycin)
ID TBA Rhabdomyosarcoma IVADo (ifosfamide, vincristine, dactinomycin, doxorubicin)
ID TBA Rhabdomyosarcoma VC (vinorelbine/cyclophosphamide oral) for maintenance
ID TBA Rhabdomyosarcoma VIRT (vincristine, irinotecan, temozolomide)  for relapse
ID Protocol
4366

Melanoma metastatic uveal tebentafusp 

(Awaiting Bispecific T cell engagers (BiTES) reference committee review)
ID Protocol
   
ID Protocol
ID 4427 Bladder/urothelial locally advanced or metastatic enfortumab vedotin and pembrolizumab
ID 4470  Renal Cell adjuvant pembrolizumab 
ID Protocol
4465 Locally advanced or metastatic larotrectinib

Send feedback for this page

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/3317

06 Oct 2024